2024年11月5日 · Cytoplasmic p16 expression (>10%), especially in combination with p53 overexpression (>50%) and MIPI-c, is a powerful prognostic marker in MCL treated with standard chemotherapy and more discriminative that p53 alone.

2024年11月5日 · Cytoplasmic p16 expression (>10%), especially in combination with p53 overexpression (>50%) and MIPI-c, is a powerful prognostic marker in MCL treated with standard chemotherapy and more discriminative that p53 alone.

2020年9月22日 · mcl是一个具有“两面性”的罕见淋巴瘤亚型，同时兼具惰性淋巴瘤，和侵袭性淋巴瘤的特征。 兼具惰性淋巴瘤特征，就意味着目前还无法治愈。 兼具侵袭性淋巴瘤特征，意味着也有可能会发展很快，需要强化疗，不像其它惰性淋巴瘤那样可以观察很多年。

2019年11月13日 · In univariate analyses, elevated levels of P16 (>10%), c-MYC (>30%) Ki67 (>40%) were associated with poorer OS and PFS in the cohort of A-MCL and C-MCL patients. There was no significant difference in survival both for OS and PFS regarding P53 (>30%).

The p16 INK4a protein is an inhibitor of the cyclin D-dependent kinases Cdk4 and Cdk6, preventing their ability to phosphorylate and inactivate the growth-suppressive retinoblastoma protein (RB).

2019年11月13日 · The aim of the present retrospective study is to investigate whether or not the CD71, c-Myc, SOX11, P53, ki67 and P16 expressions assessed by immunohistochemistry (IHC) can distinguish A-MCL from classical MCL (C-MCL).

Recent studies have suggested that co-operating aberrations of cell cycle associated genes may provide a growth advantage to a tumour. To address this issue further, we investigated five typical and three aggressive (blastoid) MCL for alterations in the cell cycle regulating genes p15, p16, CDK4, Rb and p53.

2017年12月7日 · A correlation was found between the MCL histological subtype classic or blastoid and p53 and p16 markers: blastoid type was more often observed in MCL cases expressing p53 >30% and p16 >10% (p=0.093 and p=0.034 respectively).

1997年10月15日 · Mantle cell lymphoma (MCL) has recently become generally accepted as a subentity of malignant lymphomas that is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in the overexpression of cyclin D1. Cyclin D1 forms a complex with cell cycle-dependent kinase (cdk) 4, which in …

Recently, loss-of-function mutations in cell-cycle negative regulatory elements, including p53 point mutations and deletions of the cyclin-dependent kinase inhibitors (CDKI) p15 and p16 have been described in a subset of MCLs and have been associated with aggressive clinical course, blastic morphology, and extranodal dissemination.